一名巴塞杜氏病患者的甲巯咪唑诱发全血细胞减少症:病例报告和文献综述。

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
Marcio José Concepción-Zavaleta, Juan Eduardo Quiroz-Aldave, Katia Eugenia Rivera Fabián, Sofía Pilar Ildefonso-Najarro, Karol Magdalena Moscol Chavez, Luis Alberto Concepción-Urteaga, José Paz-Ibarra
{"title":"一名巴塞杜氏病患者的甲巯咪唑诱发全血细胞减少症:病例报告和文献综述。","authors":"Marcio José Concepción-Zavaleta, Juan Eduardo Quiroz-Aldave, Katia Eugenia Rivera Fabián, Sofía Pilar Ildefonso-Najarro, Karol Magdalena Moscol Chavez, Luis Alberto Concepción-Urteaga, José Paz-Ibarra","doi":"10.2174/0115748863305536240726053827","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Methimazole is an antithyroid drug known to cause hematological toxicity, including agranulocytosis and, very rarely, pancytopenia. We herein present a case of a patient with Graves' Disease (GD) who developed methimazole-induced pancytopenia.</p><p><strong>Case report: </strong>A 53-year-old Peruvian woman with GD, initially treated with methimazole 20 mg BID, experienced odynophagia, fever, and malaise after 37 days of treatment. The initial diagnosis was agranulocytosis, leading to the discontinuation of methimazole and initiation of antibiotics. Due to persistent neutropenia, a Granulocyte Colony-stimulating Factor (G-CSF) was administered. Eight days later, she developed pancytopenia and was managed with hematopoietic agents and platelet transfusions. The patient recovered with normalization of the blood count, eliminating the need for Bone Marrow (BM) examination. Radioiodine therapy was chosen as the definitive treatment, resulting in hypothyroidism. Currently, the patient is thyroidal and hematologically stable.</p><p><strong>Conclusion: </strong>Methimazole-induced pancytopenia is a rare and serious complication; however, with appropriate treatment, complete recovery can be achieved.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Methimazole-Induced Pancytopenia in a Patient with Graves' Disease: A Case Report and Literature Review.\",\"authors\":\"Marcio José Concepción-Zavaleta, Juan Eduardo Quiroz-Aldave, Katia Eugenia Rivera Fabián, Sofía Pilar Ildefonso-Najarro, Karol Magdalena Moscol Chavez, Luis Alberto Concepción-Urteaga, José Paz-Ibarra\",\"doi\":\"10.2174/0115748863305536240726053827\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Methimazole is an antithyroid drug known to cause hematological toxicity, including agranulocytosis and, very rarely, pancytopenia. We herein present a case of a patient with Graves' Disease (GD) who developed methimazole-induced pancytopenia.</p><p><strong>Case report: </strong>A 53-year-old Peruvian woman with GD, initially treated with methimazole 20 mg BID, experienced odynophagia, fever, and malaise after 37 days of treatment. The initial diagnosis was agranulocytosis, leading to the discontinuation of methimazole and initiation of antibiotics. Due to persistent neutropenia, a Granulocyte Colony-stimulating Factor (G-CSF) was administered. Eight days later, she developed pancytopenia and was managed with hematopoietic agents and platelet transfusions. The patient recovered with normalization of the blood count, eliminating the need for Bone Marrow (BM) examination. Radioiodine therapy was chosen as the definitive treatment, resulting in hypothyroidism. Currently, the patient is thyroidal and hematologically stable.</p><p><strong>Conclusion: </strong>Methimazole-induced pancytopenia is a rare and serious complication; however, with appropriate treatment, complete recovery can be achieved.</p>\",\"PeriodicalId\":10777,\"journal\":{\"name\":\"Current drug safety\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-08-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current drug safety\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115748863305536240726053827\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863305536240726053827","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

简介:甲巯咪唑是一种抗甲状腺药物,已知可引起血液毒性,包括粒细胞减少症和极少数的全血细胞减少症。我们在此介绍一例由甲硫咪唑诱发全血细胞减少的巴塞杜氏病(GD)患者:一名 53 岁的秘鲁女性 GD 患者,最初使用甲巯咪唑 20 毫克,每日一次,治疗 37 天后出现吞咽困难、发热和乏力。初步诊断为粒细胞减少症,因此停用了甲巯咪唑,并开始使用抗生素。由于中性粒细胞减少症持续存在,医生给她注射了粒细胞集落刺激因子(G-CSF)。八天后,她出现了全血细胞减少症,接受了造血药物和血小板输注治疗。患者康复后,血细胞计数恢复正常,无需进行骨髓(BM)检查。放射性碘治疗被选为最终治疗方法,结果导致甲状腺功能减退。目前,患者甲状腺和血液状况稳定:甲巯咪唑诱发的泛发性甲状腺功能减退症是一种罕见的严重并发症;然而,通过适当的治疗,患者可以完全康复。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Methimazole-Induced Pancytopenia in a Patient with Graves' Disease: A Case Report and Literature Review.

Introduction: Methimazole is an antithyroid drug known to cause hematological toxicity, including agranulocytosis and, very rarely, pancytopenia. We herein present a case of a patient with Graves' Disease (GD) who developed methimazole-induced pancytopenia.

Case report: A 53-year-old Peruvian woman with GD, initially treated with methimazole 20 mg BID, experienced odynophagia, fever, and malaise after 37 days of treatment. The initial diagnosis was agranulocytosis, leading to the discontinuation of methimazole and initiation of antibiotics. Due to persistent neutropenia, a Granulocyte Colony-stimulating Factor (G-CSF) was administered. Eight days later, she developed pancytopenia and was managed with hematopoietic agents and platelet transfusions. The patient recovered with normalization of the blood count, eliminating the need for Bone Marrow (BM) examination. Radioiodine therapy was chosen as the definitive treatment, resulting in hypothyroidism. Currently, the patient is thyroidal and hematologically stable.

Conclusion: Methimazole-induced pancytopenia is a rare and serious complication; however, with appropriate treatment, complete recovery can be achieved.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current drug safety
Current drug safety PHARMACOLOGY & PHARMACY-
CiteScore
2.10
自引率
0.00%
发文量
112
期刊介绍: Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信